LifeMD Shares Rise on Lower Novo Nordisk GLP-1 Prices

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

LifeMD, Inc.: LifeMD to Offer Market-Leading Pricing for GLP-1 Medications Wegovy and Ozempic in Continued Collaboration with Novo Nordisk

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications ...

LifeMD Reports Third Quarter 2025 Results

Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million.Telehealth revenue grew 18% to $47.3 ...

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality careNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, ...